Affymax and Takeda Report Additional Phase 3 Clinical Trial (AFFY) - Benzinga PDF Print
Benzinga
Affymax (Nasdaq: AFFY) and Takeda Pharmaceutical Company Limited , today announced results of additional analyses from two Phase 3 studies of the investigational agent, peginesatide in chronic renal failure patients on dialysis with ...
Affymax and Takeda Report Additional Phase 3 Clinical Trial Data for

...

 
Share |
Copyright © 2026 Global Dialysis. All Rights Reserved.